Purvalanol B
| Code | Size | Price |
|---|
| SYN-1070-M100 | 100 mg | Enquire |
Quantity:
| SYN-1070-M001 | 1 mg | £69.00 |
Quantity:
| SYN-1070-M005 | 5 mg | £98.00 |
Quantity:
| SYN-1070-M010 | 10 mg | £127.00 |
Quantity:
| SYN-1070-M050 | 50 mg | £461.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
NG95
Appearance:
Solid.
CAS:
212844-54-7
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Hazards:
H303, H317, H333
InChi:
InChI=1S/C20H25ClN6O3/c1-10(2)15(8-28)24-20-25-17(16-18(26-20)27(9-22-16)11(3)4)23-12-5-6-13(19(29)30)14(21)7-12/h5-7,9-11,15,28H,8H2,1-4H3,(H,29,30)(H2,23,24,25,26)/t15-/m0/s1
InChiKey:
ZKDXRFMOHZVXSG-HNNXBMFYSA-N
Long Description:
Chemical. CAS: 212844-54-7. Formula: C20H25ClN6O3. MW: 432.9. Purvalanol B is a cyclin-dependent kinase inhibitor with IC(50) values of 6, 6, 9, > 10,000, and 6nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35, respectively. Purvalanol B has also been shown to have anti-proliferative properties, mediated by p42/p44 MAPK.
Molecular Formula:
C20H25ClN6O3
Molecular Weight:
432.9
Package Type:
Plastic Vial
Precautions:
P261, P272, P280, P302, P352, P333, P313, P321, P363, P501
Product Description:
Purvalanol B is a cyclin-dependent kinase inhibitor with IC(50) values of 6, 6, 9, > 10,000, and 6nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35, respectively. Purvalanol B has also been shown to have anti-proliferative properties, mediated by p42/p44 MAPK.
Purity:
>95%
Signal word:
Warning
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors: N.S. Gray, et al.; Science 281, 533 (1998) | ATP-site directed inhibitors of cyclin-dependent kinases: N. Gray, et al.; Curr. Med. Chem. 6, 859 (1999) | p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol: M. Knockaert, et al.; Oncogene 21, 6413 (2002)
Related Products
| Product Name | Product Code | Supplier | Purvalanol A | AG-CR1-2903 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|